Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Saito, Seiji ^a   Ohno, Kazuki ^b   Sakuraba, Hitoshi ^c  

^a HOKKAIDO INFORMATION UNIVERSITY   (Japan)

^b NPO for the Promotion of Research on Intellectual Property Tokyo   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; ATOM; COMPARATIVE STUDY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME STRUCTURE; FABRY DISEASE; GENE EXPRESSION; HUMAN; MATHEMATICAL ANALYSIS; PHENOTYPE; RESIDUE ANALYSIS; STRUCTURE ANALYSIS;

ALPHA-GALACTOSIDASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; FABRY DISEASE; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; PHENOTYPE; PROTEIN CONFORMATION;

EID: 84891323668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084267     Document Type: Article

References (27)

1. Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Sly WA, Beaudet A L, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease, eighth edition. New York: McGraw-Hill. pp. 3733-3774.
2. Nance CS, Klein CJ, Banikazemi M, Dikman SH, Phelps RG, et al. (2006) Later-onset Fabry disease: an adult variant presenting with the crampfasciculation syndrome. Arch Neurol 63: 453-457.
3. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38: 750-760. (Pubitemid 33032930)
4. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, et al. (2001) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. New Engl J Med 333: 288-293.
5. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769-775. (Pubitemid 33032933)
6. Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: Structure of human α-galactosidase. J Mol Biol 337: 319-335. (Pubitemid 38293402)
7. Garman SC (2007) Structure-function relationships in alpha-galactosidase A. Acta Paediatr Suppl 96: 6-16.
8. Sugawara K, Ohno K, Saito S, Sakuraba H (2008) Structural characterization of mutant alpha-galactosidases causing Fabry disease. J Hum Genet 53: 812-824.
9. Saito S, Ohno K, Sese J, Sugawara K, Sakuraba H (2010) Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information. J Hum Genet 55: 175-178.
10. Kundrot C, Ponder J, Richards F (1991) Algorithms for calculating excluded volume and its derivatives as a function of molecular conformation and their use in energy minimization. J Comp Chem 12: 402-409.
11. Dudek M, Ponder J (1995) Accurate modeling of the intramolecular electrostatic energy of proteins. J Comput Chem 16: 791-816.
12. Kong Y, Ponder J W (1997) Reaction field methods for off-center multipoles. J Chem Phys 107: 481-492. (Pubitemid 127564373)
13. Pappu RV, Hart RW, Ponder JW (1998) Analysis and application of potential energy smoothing for global optimization. J Phys Chem B102: 9725-9742. (Pubitemid 128591379)
14. Ren P, Ponder JW (2003) Polarizable atomic multipole water model for molecular mechanics simulation. J Phys Chem B107: 5933-5947.
15. Kabsch W (1976) A solution for the best rotation to relate two sets of vectors. Acta Crystallogr A32: 827.
16. Kabsch W (1978) A discussion of the solution for the best rotation to relate two sets of vectors. Acta Crystallogr A34: 922-923.
17. Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, et al. (2002) Molecular and structural studies of the GM2 gangliosidosis 0 variant. J Hum Genet 47: 176-183. (Pubitemid 34496177)
18. Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, et al. (2004) Structural and immunocytochemical studies on a-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J Hum Genet 49: 1-8. (Pubitemid 38186118)
19. Saito S, Ohno K, Sugawara K, Sakuraba H (2008) Structural and clinical implications of amino acid substitutions in N-acetylgalactosamine-4-sulfatase: Insight into mucopolysaccharidosis type VI. Mol Genet Metab 93: 419-425.
20. Faul F, Erdfelder E, Buchner A, Lang A-G (2009) Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods 41: 1149-1160.
21. Togawa T, Tsukimura T, Kodama T, Tanaka T, Kawashima I, et al. (2012) Fabry disease: Biochemical, pathological and structural studies of the agalactosidase A with E66Q amino acid substitution. Mol Genet Metab 105: 615-620.
22. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, et al. (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79: 31-40. (Pubitemid 43927374)
23. Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, et al. (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G.A (IVS4+919G.A). Hum Mutat 30: 1397-1405.
24. Nakamura K, Hattori K, Endo F (2011) Newborn screening for lysosomal storage disorders. Am J Med Genet 157: 63-71.
25. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, et al. (2001) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722. (Pubitemid 32202764)
26. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 345: 9-16. (Pubitemid 32634266)
27. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, et al. (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97: 3653-3670.